Drug comparisons
Galcanezumab vs Fremanezumab
Galcanezumab (Emgality) and Fremanezumab (Ajovy) both prevent migraines by blocking CGRP. They differ in dosing frequency but have similar efficacy and safety.
No comparison dimensions are available for this page.
Clinical context
Patients with chronic or episodic migraines considering CGRP inhibitor therapy may compare Galcanezumab and Fremanezumab for differences in injection frequency.
Bottom line
Both drugs are comparably effective CGRP inhibitors; selection depends on dosing preference and individual factors.
All medication comparisons